Immunologic and Clinical Failure of Antiretroviral Therapy in People Living with Human Immunodeficiency Virus within Two Years of Treatment
Open Access
- 5 May 2020
- journal article
- research article
- Published by Hindawi Limited in BioMed Research International
- Vol. 2020, 1-8
- https://doi.org/10.1155/2020/5474103
Abstract
Background. Early initiation of highly active antiretroviral therapy (HAART) decreases human immunodeficiency virus- (HIV-) related complications, restores patients’ immunity, decreases viral load, and substantially improves quality of life. However, antiretroviral treatment failure considerably impedes the merits of HAART. Objective. This study is aimed at determining the prevalence of immunologic and clinical antiretroviral treatment failure. Methods. A cross-sectional study design using clinical and immunologic treatment failure definition was used to conduct the study. Sociodemographic characteristics and clinical features of patients were retrieved from patients’ medical registry between the years 2009 and 2015. All patients who fulfilled the inclusion criteria in the study period were studied. Predictors of treatment failure were identified using Kaplan-Meier curves and multivariable Cox regression analysis. Data analysis was done using SPSS version 21 software, and the level of statistical significance was declared at a value < 0.05. Results. A total of 770 were studied. The prevalence of treatment failure was 4.5%. The AZT-based regimen ( , 95% CI: 3.02-95.1,This publication has 37 references indexed in Scilit:
- Prevalence and Predictors of Immunological Failure among HIV Patients on HAART in Southern EthiopiaPLOS ONE, 2015
- The effect of incident tuberculosis on immunological response of HIV patients on highly active anti-retroviral therapy at the university of Gondar hospital, northwest Ethiopia: a retrospective follow-up studyBMC Infectious Diseases, 2014
- Predictors of treatment failure and time to detection and switching in HIV-infected Ethiopian children receiving first line anti-retroviral therapyBMC Infectious Diseases, 2012
- Immunologic and clinical outcomes of children on HAART: A retrospective cohort analysis at Jimma University Specialized HospitalEthiopian Journal of Health Sciences, 2011
- Adverse Effects of Highly Active Anti-Retroviral Therapy (HAART)Journal of Antivirals & Antiretrovirals, 2011
- Determinants of survival in adult HIV patients on antiretroviral therapy in Oromiyaa, EthiopiaGlobal Health Action, 2010
- Impact of highly active antiretroviral therapy (HAART) on the incidence of opportunistic infections, hospitalizations and mortality among children and adolescents living with HIV/AIDS in Belo Horizonte, Minas Gerais State, Brazil.Cadernos de Saude Publica, 2007
- Lessons Learned from Use of Highly Active Antiretroviral Therapy in AfricaClinical Infectious Diseases, 2005
- Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected childrenThe Pediatric Infectious Disease Journal, 2003
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionThe New England Journal of Medicine, 1998